The use of IL-6 or IL-6r inhibitors, such as sarilumab or tocilizumab, is approved for the treatment of immune related toxicities, autoimmune diseases such as arthritis rheumatoid, and of cytokine release syndrome from CAR-T or Tebentafusp. The gene discussed is IL6R; the disease is rheumatoid arthritis.